Comparison · NCT01955980-b0ec5b4f
Buparid; Treatment A vs Budes; Treatment B: Safety Assessment
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Buparid; Treatment A vs Budes; Treatment B: Safety Assessment. Trial comparisons, record NCT01955980-b0ec5b4f. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01955980-b0ec5b4f
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.6 | 0.313 | 0.832 | wilson | |
| Risk in group 2 | 0.667 | 0.354 | 0.879 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0667 | -0.424 | 0.322 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.9 | 0.454 | 1.79 | log | |
| Odds ratio, group 1 over group 2 | 0.75 | 0.115 | 4.9 | log | |
| Number needed to treat, for one fewer participant with the outcome on Buparid; Treatment A than on Budes; Treatment B | 15 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Buparid; Treatment A | Buparid 1mg budesonide/2 ml nebulizer solution~Budesonide: Inhalation Solution | 6 | 10 | OG000 |
| Group 2 | Budes; Treatment B | Budes Nasal Spray 50 µg budesonide/pump~Budesonide: Nasal Spray | 6 | 9 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Safety Assessment
- Description
- Treatment-emergent adverse events
- Time frame
- 48 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis
- NCT number
- NCT01955980
- Phases
- PHASE1, PHASE2
- Conditions
- Rhinosinusitis
- Interventions
- Budesonide, Budesonide
- Lead sponsor
- Pari Pharma GmbH
- Results first posted
- 2022-04-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01955980?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01955980-b0ec5b4f